APA (7th ed.) Citation

Gumbinger, C., Reuter, B., Stock, C., Sauer, T., Kern, R., Ringleb, P. A., . . . Hacke, W. (2014). Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: Retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. The BMJ, 348, . https://doi.org/10.1136/bmj.g3429

Chicago Style (17th ed.) Citation

Gumbinger, Christoph, Björn Reuter, Christian Stock, Tamara Sauer, Rolf Kern, Peter A. Ringleb, Michael G. Hennerici, and Werner Hacke. "Time to Treatment with Recombinant Tissue Plasminogen Activator and Outcome of Stroke in Clinical Practice: Retrospective Analysis of Hospital Quality Assurance Data with Comparison with Results from Randomised Clinical Trials." The BMJ 348 (2014). https://doi.org/10.1136/bmj.g3429.

MLA (9th ed.) Citation

Gumbinger, Christoph, et al. "Time to Treatment with Recombinant Tissue Plasminogen Activator and Outcome of Stroke in Clinical Practice: Retrospective Analysis of Hospital Quality Assurance Data with Comparison with Results from Randomised Clinical Trials." The BMJ, vol. 348, 2014, https://doi.org/10.1136/bmj.g3429.